- Faculty
- Health
- In the News
Ph I CA-4948 in Comb w/ Gemcitabine and Nab-Paclitaxel in Meta or UnresePancreatic Ductal Carcinoma
Farshid Dayyani
A Study On:
- Pancreas
Status:
- Open
Eligibility
Adult
Interested in joining this trial?
Official Title
A Phase I Clinical Trial of CA-4948 in Combination with Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma
Details
This phase I trial tests the safety, side effects, and best dose of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in treating patients with pancreatic ductal adenocarcinoma that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable). CA-4948 is in a class of medications called kinase inhibitors. It works by blocking the action of abnormal proteins called interleukin-1 receptor-associated kinase 4 (IRAK4) and FMS-like tyrosine kinase 3 (FLT3) that signal cells to multiply. This may help keep cancer cells from growing. The usual approach for patients with pancreatic ductal adenocarcinoma is treatment with chemotherapy drugs gemcitabine and nab-paclitaxel. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill cancer cells. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. Giving CA-4948 in combination with gemcitabine and nab-paclitaxel may shrink or stabilize metastatic or unresectable pancreatic ductal adenocarcinoma.
Eligibility
You can join if...
Inclusion Criteria-Adults 18 years of age or older
-Patients with confirmed adenocarcimona of the pancreas that is metastatic or unresectable and for which standard curative or palliative measure do not exist or are no longer effective.
Exclusion Criteria
-Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
-Patients who are receiving any other investigational agents
-Patients who are pregnant
Get in touch with our study team
News & Events
UCI Health enrolls patient in first U.S. study of medical device for erectile dysfunction Sickle cell disease treatment nearing FDA approval - Faculty
- Health
- In the News
His GERD is now a distant memory - Faculty
- Health
- In the News